Line extensions start from a constraint that new launches do not have: something is already on shelf, already claimed, and already built on a particular material. Adding a Palmitoyl Pentapeptide-4 SKU to that range is less a sourcing decision than a consistency decision — whether the new product can share the existing material and specification, and what has to be revalidated where it cannot. This page works through that, and through the cases where adding the ingredient is not the right move.
What you are actually buying
Palmitoyl Pentapeptide-4 is a lipidated pentapeptide, Pal-Lys-Thr-Thr-Lys-Ser (Pal-KTTKS), CAS 214047-00-4, molecular formula C39H75N7O10, molecular weight approximately 802. Two naming facts matter when an existing range is involved:
- Palmitoyl Pentapeptide-3 was the earlier INCI name for the same substance, renamed in 2006. Legacy formulas and older documents may still carry it.
- Matrixyl™ is a trade name of Sederma SAS for their branded material. It is not a generic descriptor. We supply the INCI ingredient, not that company's branded product, and hold no authorisation to represent it. If the existing product in your range was built on the branded material, moving to an INCI-equivalent from another supplier is a material change and should be treated as one.
Commercially the ingredient shows up as neat peptide, as dilutions and solutions at stated concentrations, and inside proprietary blends. As with the rest of this category, purity and active concentration are different figures: purity describes the detected material, while active concentration describes how much peptide is in what you receive. Only the second normalises a price or a dose.
Should the new SKU share the existing specification?
Answer this before quoting, because it decides how much work follows. Sharing one material and one specification across both SKUs keeps documentation, supplier management and forecasting simple, and it keeps the ingredient story coherent. It also means any future supplier change touches both products at once.
Sharing is usually workable when the new format is close to the existing one in base chemistry and pH, when both can tolerate the same specification ranges, and when the volumes justify holding one material to a tighter standard. It breaks down when the new format needs a different material form — a solution rather than a powder for a different manufacturing setup, for instance — because at that point you are managing two materials regardless of what the INCI declaration says.
What a line extension revalidates
A shared ingredient does not transfer test results. Even holding the material identical, the new SKU needs its own compatibility work in its own base, its own finished-product stability in its own packaging, and its own safety assessment. What genuinely carries across is the material qualification: identity, documentation, supplier review, and the specification itself.
Where the material form does change, treat it as a new qualification rather than a variation, and expect the stability programme to start again. The specification sheet checklist is the practical place to confirm what is fixed before packaging copy is written.
Keeping the ingredient story consistent
If the existing product's marketing already describes this peptide, the extension has to say something compatible. Two failure modes are common enough to name: describing the same ingredient in stronger terms on the newer product than on the original, and letting the trade name from the original formulation carry over onto a product built on a different supplier's material. Both are claims problems that surface at artwork stage, and both are cheaper to prevent than to reprint. Target-market claims review applies to the extension in its own right, not by inheritance.
When not to add it
Adding this peptide is the wrong call when the range already carries it in a neighbouring SKU and the extension would compete with itself; when the new format's base chemistry has not been tested against it and the timeline has no room for a stability run; or when the ingredient is being added to justify a price step rather than to do formulation work. In those cases it belongs on the list as a supporting peptide for a later reformulation, not in this extension. On where this ingredient still earns its place, see our note on that question.
What we can support
We supply Palmitoyl Pentapeptide-4 with COA and SDS/MSDS documentation, a specification sheet with purity information, samples for formulation evaluation, and bulk quotation against a stated quantity and destination market. For an extension it is worth stating the existing SKU's material form and specification at inquiry stage so the offer can be matched to it. Specification scope is on the Palmitoyl Pentapeptide-4 material page, and the broader cosmetic peptide picture is mapped in our ingredient sourcing map.
Frequently Asked Questions
Is Matrixyl the same as Palmitoyl Pentapeptide-4?
Matrixyl™ is a trade name of Sederma SAS for their branded material containing this peptide. Palmitoyl Pentapeptide-4 is the INCI ingredient, CAS 214047-00-4. We supply the INCI ingredient and do not represent the trademark owner.
Is Palmitoyl Pentapeptide-3 a different ingredient?
No. It is the earlier INCI name for the same substance, renamed to Palmitoyl Pentapeptide-4 in 2006. Older formulas and documents may still use it.
Can the extension reuse the original SKU's stability data?
No. Stability is a property of the finished formula in its packaging, so the new SKU needs its own programme even when the raw material and specification are identical.